These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

697 related articles for article (PubMed ID: 26406300)

  • 1. American Society of Addiction Medicine (ASAM) National Practice Guideline for the Use of Medications in the Treatment of Addiction Involving Opioid Use.
    Kampman K; Jarvis M
    J Addict Med; 2015; 9(5):358-67. PubMed ID: 26406300
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Systematic Review on the Use of Psychosocial Interventions in Conjunction With Medications for the Treatment of Opioid Addiction.
    Dugosh K; Abraham A; Seymour B; McLoyd K; Chalk M; Festinger D
    J Addict Med; 2016; 10(2):93-103. PubMed ID: 26808307
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Criminal justice continuum for opioid users at risk of overdose.
    Brinkley-Rubinstein L; Zaller N; Martino S; Cloud DH; McCauley E; Heise A; Seal D
    Addict Behav; 2018 Nov; 86():104-110. PubMed ID: 29544869
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Executive Summary of the Focused Update of the ASAM National Practice Guideline for the Treatment of Opioid Use Disorder.
    Crotty K; Freedman KI; Kampman KM
    J Addict Med; 2020; 14(2):99-112. PubMed ID: 32209915
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Statement of the American Society Of Addiction Medicine Consensus Panel on the use of buprenorphine in office-based treatment of opioid addiction.
    Kraus ML; Alford DP; Kotz MM; Levounis P; Mandell TW; Meyer M; Salsitz EA; Wetterau N; Wyatt SA;
    J Addict Med; 2011 Dec; 5(4):254-63. PubMed ID: 22042215
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Medication-assisted treatment of opioid use disorder: review of the evidence and future directions.
    Connery HS
    Harv Rev Psychiatry; 2015; 23(2):63-75. PubMed ID: 25747920
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Buprenorphine and naloxone access in pharmacies within high overdose areas of Los Angeles during the COVID-19 pandemic.
    Dadiomov D; Bolshakova M; Mikhaeilyan M; Trotzky-Sirr R
    Harm Reduct J; 2022 Jun; 19(1):69. PubMed ID: 35768817
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Opioid Use Disorders.
    Sharma B; Bruner A; Barnett G; Fishman M
    Child Adolesc Psychiatr Clin N Am; 2016 Jul; 25(3):473-87. PubMed ID: 27338968
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevention of Opioid Overdose.
    Babu KM; Brent J; Juurlink DN
    N Engl J Med; 2019 Jun; 380(23):2246-2255. PubMed ID: 31167053
    [No Abstract]   [Full Text] [Related]  

  • 10. The science and practice of medication-assisted treatments for opioid dependence.
    Pecoraro A; Ma M; Woody GE
    Subst Use Misuse; 2012; 47(8-9):1026-40. PubMed ID: 22676570
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Perioperative Considerations for the Patient with Opioid Use Disorder on Buprenorphine, Methadone, or Naltrexone Maintenance Therapy.
    Harrison TK; Kornfeld H; Aggarwal AK; Lembke A
    Anesthesiol Clin; 2018 Sep; 36(3):345-359. PubMed ID: 30092933
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The case for a medication first approach to the treatment of opioid use disorder.
    Winograd RP; Presnall N; Stringfellow E; Wood C; Horn P; Duello A; Green L; Rudder T
    Am J Drug Alcohol Abuse; 2019; 45(4):333-340. PubMed ID: 31084515
    [No Abstract]   [Full Text] [Related]  

  • 13. Long-term course of opioid addiction.
    Hser YI; Evans E; Grella C; Ling W; Anglin D
    Harv Rev Psychiatry; 2015; 23(2):76-89. PubMed ID: 25747921
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Opioid addiction and abuse in primary care practice: a comparison of methadone and buprenorphine as treatment options.
    Bonhomme J; Shim RS; Gooden R; Tyus D; Rust G
    J Natl Med Assoc; 2012; 104(7-8):342-50. PubMed ID: 23092049
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Geographic and specialty distribution of US physicians trained to treat opioid use disorder.
    Rosenblatt RA; Andrilla CH; Catlin M; Larson EH
    Ann Fam Med; 2015; 13(1):23-6. PubMed ID: 25583888
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Deploying science to change hearts and minds: Responding to the opioid crisis.
    Walsh SL; Long KQX
    Prev Med; 2019 Nov; 128():105780. PubMed ID: 31319116
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Test of a workforce development intervention to expand opioid use disorder treatment pharmacotherapy prescribers: protocol for a cluster randomized trial.
    Molfenter T; Knudsen HK; Brown R; Jacobson N; Horst J; Van Etten M; Kim JS; Haram E; Collier E; Starr S; Toy A; Madden L
    Implement Sci; 2017 Nov; 12(1):135. PubMed ID: 29141653
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The diverse clinical uses of opioid receptor drugs.
    Howland RH
    J Psychosoc Nurs Ment Health Serv; 2010 May; 48(5):11-4. PubMed ID: 20415289
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Consensus statement on office-based treatment of opioid dependence using buprenorphine.
    Fiellin DA; Kleber H; Trumble-Hejduk JG; McLellan AT; Kosten TR
    J Subst Abuse Treat; 2004 Sep; 27(2):153-9. PubMed ID: 15450648
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of opioid use disorders: a national clinical practice guideline.
    Bruneau J; Ahamad K; Goyer MÈ; Poulin G; Selby P; Fischer B; Wild TC; Wood E;
    CMAJ; 2018 Mar; 190(9):E247-E257. PubMed ID: 29507156
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 35.